Biotechnology News

July 1, 2014

PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that it has submitted a Supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) for Somatuline® Depot 120mg injection for the...

June 30, 2014

SAN DIEGO--(BUSINESS WIRE)--Batu Biologics Inc, an immunotherapy company developing ValloVaxTM, the first anti-angiogenic cancer vaccine, announced today the appointment of Boris Minev, M.D. to the company’s Scientific Advisory Board (SAB). Dr....

June 30, 2014

ANN ARBOR, Mich.--(BUSINESS WIRE)--Michigan’s biosciences industry saw significant gains according to the Battelle/BIO State Bioscience Jobs, Investments and Innovation 2014 report released last week during the annual BIO International Convention...

June 30, 2014

PITTSBURGH--(BUSINESS WIRE)--Cell biologists have a new imaging and analysis software available to them that offers speed, flexibility and efficiency for large-scale, high-throughput biology, including complex morphological analyses of cells,...

June 30, 2014

CAMBRIDGE, Mass. & SEATTLE--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced the acquisition...

June 30, 2014

BOSTON--(BUSINESS WIRE)--Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for Use of KALYDECO® (ivacaftor) in People 18 and Older with Cystic Fibrosis who have the R117H Mutation

June 30, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIOGEN IDEC TO REPORT SECOND QUARTER 2014 FINANCIAL RESULTS ON JULY 23, 2014

June 30, 2014

BOSTON--(BUSINESS WIRE)--Boston Strategics Corporation (BSC), an integrated clinical-stage drug research and development (R&D) company, Boston, MA, today announced that it has entered into an exclusive licensing and development agreement with...

June 30, 2014

HOUSTON--(BUSINESS WIRE)--CompanionDx Reference Lab, a high-complexity CLIA certified laboratory specializing in pharmacogenomics, cancer companion diagnostics, targeted next generation sequencing (NGS) and epigenomics testing, is proud to join...

June 30, 2014

CLARENCE, N.Y.--(BUSINESS WIRE)--22nd Century Group, Inc. (NYSE MKT: XXII) today announced that the Company joined the Russell 3000, Russell 2000, Russell Global and Russell Microcap Indexes.

June 30, 2014

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced closing of its underwritten public offering of 4,751,358 shares of common stock at a public offering price of $11....

June 30, 2014

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an innovative company specializing in the development of drugs for orphan oncology diseases, and Topotarget A/S (NASDAQ...

June 30, 2014

DENVER--(BUSINESS WIRE)--Colorado BioScience Association (CBSA) is honored to welcome the United States Patent and Trademark Office (USPTO) Rocky Mountain Regional Satellite Office to Denver.

June 30, 2014

NEW YORK--(BUSINESS WIRE)--Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced...

June 30, 2014

MIAMI--(BUSINESS WIRE)--Brickell Biotech, Inc. (“Brickell“), a clinical-stage pharmaceutical company focused on the development of differentiated, innovative therapeutics to satisfy current unmet human needs in the global dermatology markets,...

June 30, 2014

GREENSBORO, N.C.--(BUSINESS WIRE)--Merz North America, Inc. today announced that it has signed an agreement with Brickell Biotech, Inc. granting Merz an exclusive North American license with certain additional international rights to develop and...

June 30, 2014

MADISON, Wis.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes LLC has signed the Radioxenon Emissions Pledge with the Preparatory Commission for the Comprehensive Nuclear-Test-Ban Treaty Organization.

June 30, 2014

ST. LOUIS--(BUSINESS WIRE)--Washington University in St. Louis has licensed its proprietary genetic sequencing tool to PierianDx, opening the door for other clinical labs to do their own next-generation sequencing.

June 30, 2014

THE WOODLANDS, Texas--(BUSINESS WIRE)--US Oncology Research and Baylor College of Medicine have recently launched a clinical trial to study a scalp cooling system designed to prevent chemotherapy-induced hair loss (alopecia).

June 30, 2014

SAN ANTONIO--(BUSINESS WIRE)--Healthcare industry veteran to spearhead next generation of interoperability and mobility innovations; AirStrip also names Gabriela Tobal new Director of Culture and Operational Excellence

June 30, 2014

BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--In work published in Nature this month, scientists at the Broad Institute and Fluidigm used the C1 Single-Cell Auto Prep System to prepare cells for single-cell sequencing.

June 30, 2014

SUNNYVALE, Calif.--(BUSINESS WIRE)--Icon Bioscience completes patient enrollment in phase 3 study of IBI-10090 for inflammation post cataract surgery. Enrollment completed approximately four months ahead of projected timelines.

June 30, 2014

HEIDELBERG, Germany--(BUSINESS WIRE)--Affimed Files Registration Statement for Proposed Initial Public Offering

June 30, 2014

DUBLIN, Ireland--(BUSINESS WIRE)--Announcement under Irish Takeover Rules Relevant Securities in Issue – June 30, 2014

June 30, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oliver Rosen, M.D., appointed as Chief Medical Officer responsible for leading Deciphera's clinical development strategy and clinical operations

June 30, 2014

HOUSTON--(BUSINESS WIRE)--Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that the Company’s common stock has been added to the...

June 30, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) announced today that InVivo’s Director of Research Richard Layer, Ph.D., has been invited to speak at the Joint Symposium of the 4th International Neural Regeneration...

June 30, 2014

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today announced updates on three of the Company’s key R&D pipeline programs, including abicipar pegol (Anti-VEGF DARPin®), bimatoprost sustained-release...

June 30, 2014

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck Announces Data from Investigational Phase 3 Study on EMEND® (aprepitant) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Undergoing Emetogenic Chemotherapy.

June 30, 2014

SAN DIEGO, Calif.--(BUSINESS WIRE)--Cidara Therapeutics Completes $32 Million Series A Financing

June 30, 2014

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Quintiles Transnational Holdings Inc. (NYSE: Q) will release its financial results for the second quarter of 2014 prior to its quarterly earnings call on Thursday, July 31, 2014, at 8:00 a.m. EDT.

June 30, 2014

THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), today announced its addition to the Russell Microcap® Index.

June 30, 2014

WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals announced preclinical data demonstrating the promise of DCR-PH1, the Company’s therapeutic candidate for the treatment of primary hyperoxaluria type 1 (PH1).

June 30, 2014

MALVERN,Pa.--(BUSINESS WIRE)--Aclaris Therapeutics Announces Positive Results from Phase 2 Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Skin Tumor

June 30, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) has approved LemtradaTM (alemtuzumab) for adult...

June 30, 2014

JUPITER, Fla.--(BUSINESS WIRE)--BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCBB:BRTX), a life sciences company focused on adult stem cell-based cellular therapies for various personal medical applications, today announced the...

June 30, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has been added to the Russell 1000 Index, effective June 27, 2014. The Russell 1000 Index measures the...

June 30, 2014

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company Added to the Russell Microcap Index

June 30, 2014

PORTLAND, Ore.--(BUSINESS WIRE)--Sedia Biosciences will give a scientific presentation on a new rapid HIV incidence assay at the July 2014 International AIDS Conference in Melbourne, Australia. We will also have a commercial exhibit.

June 30, 2014

NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE:ENZ) announced today the company was added to the Russell 2000® and Russell 3000® Indexes following the reconstitution of Russell Investment Group's family of US indexes after the market closed...

June 30, 2014

HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc.(NASDAQ:HART), announces its HART-Trachea was spotlighted in a two-hour-long NBC-TV News Special on Friday, June 27.

June 30, 2014

LAS VEGAS--(BUSINESS WIRE)--Medican Enterprises, Inc. (OTCBB:MDCN) a bio-pharmaceutical company in the emerging global medical marijuana industry is pleased to announce it is currently negotiating the purchase of 51% of International Herbs...

June 30, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on harnessing the potential of hypoxia-inducible factor (HIF) biology to develop and commercialize novel therapeutics to treat kidney...

June 30, 2014

INGELHEIM, Germany--(BUSINESS WIRE)--For media outside of the U.S., the UK & Canada only The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational antidote idarucizumab* (a humanized...

June 30, 2014

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--MSD’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma.